Arthur L. Corbin

Array ( [id] => 20628009 [patent_doc_number] => 20260092293 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-02 [patent_title] => EXPRESSION-ADJUSTABLE ENGINEERED RNA MOLECULE [patent_app_type] => utility [patent_app_number] => 19/408745 [patent_app_country] => US [patent_app_date] => 2025-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19408745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20548935 [patent_doc_number] => 12559717 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-24 [patent_title] => Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes [patent_app_type] => utility [patent_app_number] => 19/192918 [patent_app_country] => US [patent_app_date] => 2025-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 25 [patent_no_of_words] => 11372 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 189 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19192918 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20059249 [patent_doc_number] => 20250197471 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-19 [patent_title] => METHODS FOR THE TREATMENT OF B CELL MALIGNANCIES USING ADOPTIVE CELL THERAPY [patent_app_type] => utility [patent_app_number] => 19/031042 [patent_app_country] => US [patent_app_date] => 2025-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19031042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20158398 [patent_doc_number] => 12385010 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-12 [patent_title] => Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes [patent_app_type] => utility [patent_app_number] => 18/933687 [patent_app_country] => US [patent_app_date] => 2024-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 25 [patent_no_of_words] => 11251 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18933687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19098155 [patent_doc_number] => 20240117383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => SELECTION BY ESSENTIAL-GENE KNOCK-IN [patent_app_type] => utility [patent_app_number] => 18/537754 [patent_app_country] => US [patent_app_date] => 2023-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 111914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18537754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125716 [patent_doc_number] => 20240131069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 18/501621 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22474 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501621 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19491807 [patent_doc_number] => 12110504 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-08 [patent_title] => Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes [patent_app_type] => utility [patent_app_number] => 18/501837 [patent_app_country] => US [patent_app_date] => 2023-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 25 [patent_no_of_words] => 15746 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 285 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125716 [patent_doc_number] => 20240131069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => ADMINISTRATION OF TUMOR INFILTRATING LYMPHOCYTES WITH MEMBRANE BOUND INTERLEUKIN 15 TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 18/501621 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22474 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18501621 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18923300 [patent_doc_number] => 20240026304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => Method for Producing Stem Cell Clones Suitable for Induction of Differentiation into Somatic Cells [patent_app_type] => utility [patent_app_number] => 18/476065 [patent_app_country] => US [patent_app_date] => 2023-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18476065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464530 [patent_doc_number] => 20240318199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => ADENO-ASSOCIATED VIRUS (AAV) SYSTEMS FOR TREATMENT OF PROGRANULIN ASSOCIATED NEURODEGENERATIVE DISEASES OR DISORDERS [patent_app_type] => utility [patent_app_number] => 18/372868 [patent_app_country] => US [patent_app_date] => 2023-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18372868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860235 [patent_doc_number] => 20230414669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => PRODUCTION METHOD FOR THERAPEUTIC AGENT FOR ARTHROSIS, AND THERAPEUTIC AGENT FOR ARTHROSIS [patent_app_type] => utility [patent_app_number] => 18/463631 [patent_app_country] => US [patent_app_date] => 2023-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18463631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170900 [patent_doc_number] => 20240156874 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/242495 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10832 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18242495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19381220 [patent_doc_number] => 20240271090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell Therapy [patent_app_type] => utility [patent_app_number] => 18/459533 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459533 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402228 [patent_doc_number] => 20240285739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => MULTIEPITOPE VACCINE CASSETTES [patent_app_type] => utility [patent_app_number] => 18/458062 [patent_app_country] => US [patent_app_date] => 2023-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61030 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18458062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19051224 [patent_doc_number] => 20240093193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS [patent_app_type] => utility [patent_app_number] => 18/449940 [patent_app_country] => US [patent_app_date] => 2023-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 113251 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18449940 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125838 [patent_doc_number] => 20240131191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING GAMMA DELTA T CELLS IN THE GUT [patent_app_type] => utility [patent_app_number] => 18/448811 [patent_app_country] => US [patent_app_date] => 2023-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25680 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032537 [patent_doc_number] => 20240082352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => REGENERATING FUNCTIONAL NEURONS FOR TREATMENT OF NEURAL INJURY CAUSED BY DISRUPTION OF BLOOD FLOW [patent_app_type] => utility [patent_app_number] => 18/448421 [patent_app_country] => US [patent_app_date] => 2023-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23981 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19111340 [patent_doc_number] => 20240123090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-18 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING GAMMA DELTA T CELLS IN THE GUT [patent_app_type] => utility [patent_app_number] => 18/448807 [patent_app_country] => US [patent_app_date] => 2023-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19020523 [patent_doc_number] => 20240076694 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => COMPOSITION COMPRISING RAAV CONTAINING SOLUBLE VEGFR-1 VARIANT CDNA FOR TREATMENT OF MACULAR DEGENERATION [patent_app_type] => utility [patent_app_number] => 18/365015 [patent_app_country] => US [patent_app_date] => 2023-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8266 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18365015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19157721 [patent_doc_number] => 20240150428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => GENOME-EDITED INVARIANT NATURAL KILLER T (INKT) CELLS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 18/340417 [patent_app_country] => US [patent_app_date] => 2023-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23771 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18340417 [rel_patent_id] =>[rel_patent_doc_number] =>)